AdvantTIG-302: Anti-TIGIT monoclonal antibody ociperlimab+tislelizumab in non-small cell lung cancer

Makoto Nishio,1 Mark A. Socinski,2 Alex Spira,3 Luis Paz-Ares,4 Martin Reck,5 Shun Lu,6 Tao Sheng,7 Sandra Chica-Duque,7 Xinmin Yu8

1The Cancer Institute Hospital of JFCR, Tokyo, Japan; 2AdventHealth Cancer Institute, Orlando, FL, USA; 3Virginia Cancer Specialists, US Oncology Research. The US Oncology Network, New York University, Fairfax, VA, USA; 4Department of Medical Oncology, Hospital Universitario 12 De Octubre, Madrid, Spain; 5Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany; 6Shanghai Chest Hospital, Shanghai, China; 7BeiGene (US) Co., Ltd., NJ, USA; 8Department of Medical Oncology, Cancer Hospital of University of Chinese Academy of Sciences & Zhejiang Cancer Hospital, Hangzhou, China.

Background: Ociperlimab (OCI, BGB-A1217), a humanized monoclonal antibody, binds T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) with high affinity/specificity, inducing cytotoxicity. Here, we report design of a trial investigating synergistic antitumor activity of dual anti-TIGIT and anti-PD-1 antibody targeting.

Methods: AdvantTIG-302 is a Phase 3, international, randomized, double-blind study (NCT04746924) investigating OCI+tislelizumab (TIS) vs pembrolizumab (PEM) in adults with PD-L1 selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer without oncogenic EGFR or ALK mutation. About 660 pts will be randomized 5:5:2 to IV OCI 900mg+TIS 200mg Q3W, PEM 200mg+placebo Q3W, or TIS 200mg+placebo Q3W. Pts will be treated until disease progression, loss of clinical benefit, or intolerable toxicity. Stratification factors include histology and region. Cross-over is not permitted. Key eligibility criteria include histologically confirmed disease, PD-L1 expression ≥50%, and no prior checkpoint inhibitor therapy.

Results: Dual primary endpoints are progression-free survival by investigator (PFS; RECIST v1.1) and overall survival. Secondary endpoints include PFS (Blinded Independent Review Committee), overall response rate and duration of response, safety and tolerability, and health-related quality of life. Exploratory endpoints include disease control rate, clinical benefit rate and time to response. Biomarkers will be evaluated.

JLCS 2023
Conclusions: Study recruitment is ongoing.